Last reviewed · How we verify
Candesartan and Hydrochlorothiazide
At a glance
| Generic name | Candesartan and Hydrochlorothiazide |
|---|---|
| Also known as | BLOPRESS PLUS® |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- The Precision Hypertension Care Study (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323 (PHASE1)
- Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control (PHASE3)
- Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control (PHASE3)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candesartan and Hydrochlorothiazide CI brief — competitive landscape report
- Candesartan and Hydrochlorothiazide updates RSS · CI watch RSS
- Takeda portfolio CI